| Low-Carb Diet Cures Severe Case Of GERD
Nothing proves the health benefits of livin' la vida low-carb better than real people sharing their own experiences following this amazing lifestyle change. That's exactly what I found in this Spokesman-Review Q&A health column featuring syndicated health columnists Joe and Teresa Graedon.Interestingly, I've featured the Graedon's before at my blog when another one of their readers told them how the low-carb lifestyle not only helped control his weight and blood sugar, but completely eliminated his heartburn.This latest letter featured someone who used to suffer from gastroesophageal reflux disease, or GERD. He said the condition was so bad that it forced him to take Prilosec every single day."Even so, I had severe heartburn, and often food got lodged in my esophagus, even after it was surgically stretched," he wrote.
Schering-Plough Net Rises on Cholesterol Drugs' Sales (Update5)
Jan. 29 (Bloomberg) -- Schering-Plough Corp.'s fourth- quarter earnings surged 62 percent as the combined sales of its Vytorin and Zetia cholesterol drugs jumped to $1.1 billion. Net income rose to $204 million, or 12 cents a share, from $126 million, or 7 cents, a year earlier, the Kenilworth, New Jersey-based company said today in a statement. Revenue increased 14 percent to $2.7 billion, spurred by a 46 percent rise for Zetia and Vytorin. Chief Executive Officer Fred Hassan closed plants and fired 2,000 workers to cut $100 million in 2007 costs. Schering, the eighth-biggest drugmaker by sales, said it expects revenue from the company's cholesterol drugs to increase this year even as the treatments face competition from generic copies of Merck & Co.'s Zocor.
Schering-Plough Q4 Profit Increases On Higher Prescription Drug ...
(RTTNews) - Monday morning, healthcare company Schering-Plough Corp. (SGP | charts | news | PowerRating), revealed fourth quarter results, reporting an increase in net income available to common shareholders, on a 14% increase in revenues. Net income for the quarter includes a negative impact related to actions taken to streamline the company's manufacturing operations and a charge related to the licensing of an over-the counter or OTC treatment of Zegerid for heartburn. Net sales for the quarter increased 14%, on strong growth in sales of prescription drugs Remicade, Nasonex and Temodar, as well as higher sales from its cholesterol joint venture with Merck & Co. (MRK | charts | news | PowerRating). Q4 Results On a GAAP basis, the Kenilworth, New Jersey-based company's fourth-quarter net income increased to $204 million from $126 million in the last-year quarter.
Bill would impact juvenile justice
Prosecutors may feel a little heartburn under a House proposal requiring parents' permission before using a child's confession in court. House Bill 727, approved Thursday by the Juvenile Justice Committee, would require parental permission to use the confession of a child younger than 17 if the suspect talked to police without a parent or attorney present. Representatives could vote on the measure as early as next week. Ronnie Harper, former president of the Mississippi Prosecutors Association, said the bill could have a significant impact on cases. "That's a pretty far-reaching requirement for such a large group of people," said Harper, who suggested lawmakers consider a lower age ceiling than 17. Parents who have children in custody said more protective measures are needed.
|
